Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XBP1- or ATF6-mediated UPR pathway.

Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XB1- or ATF6-mediated UPR pathway.

Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XB1- or ATF6-mediated UPR pathway.

Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XBP1- or ATF6-mediated UPR pathway.

Abstract: The present invention is based on observations that transiently transfecting large-scale eukaryotic cell cultures with a polynucleotide encoding a protein of interest can be used to rapidly produce the large quantities of labeled proteins required for various biochemical techniques such as spectroscopy, microscopy, and crystallography, and applications including protein structure determination, protein tracing and/or localization, diagnostic and therapeutic applications, and affinity experiments. Thus, the present invention provides methods for rapidly producing large quantities of labeled proteins by using transient transfection of large-scale eukaryotic cell cultures, which are then grown in a chemically defined labeling medium that includes labeled amino acids. The present invention is also directed to methods of using the labeled proteins produced by the novel labeling methods for use in various techniques.

Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XBP1- or ATF6-mediated UPR pathway.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Beta enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel GDP-mannose 4,6-dehydratase.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel GDP-mannose 4,6-dehydratase.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Beta enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel GDP-mannose 4,6-dehydratase.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Beta enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Beta enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel GDP-mannose 4,6-dehydratase.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2-Beta enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.

Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A.sub.2 -Gamma enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.